Navigation Links
Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
Date:9/25/2008

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that Dr. Dennis Kim has joined the Company as Senior Vice President and Head of Obesity and Metabolic Disorders. Dr. Kim will be leading the clinical development activities for the Company's obesity franchise.

"I am thrilled to be joining the team at Orexigen at such an exciting time," said Dr. Kim. "I'm looking forward to working with the leadership team at Orexigen to bring to market our two obesity treatment candidates, Contrave(R) and Empatic(TM)."

Dr. Kim brings more than seven years of pharmaceutical experience to Orexigen. He joins the Company from EnteroMedics, Inc., where he served as Chief Medical Officer and Vice President of Medical Affairs. Prior to that, Dr. Kim worked at Amylin Pharmaceuticals where he was Executive Director, Corporate Strategy. There, he played a significant role in the Company's alliance with Eli Lilly, including the development and launch of Byetta(R).

Dr. Kim holds an M.D. from the Chicago Medical School. He completed his internal medicine residency at Rush Presbyterian St. Luke's Medical Center and an endocrinology fellowship at the University of California, San Diego (USCD) School of Medicine. Dr. Kim also holds a Master of Business Administration degree from UCSD's Rady School of Business.

"Orexigen focuses on expertise, experience and excellence in addressing senior management positions," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "Dr. Kim will be a key addition to Orexigen, bringing not only a deep expertise in obesity and metabolic disorders to the Company, but also a strong background in strategy, medical affairs and management."

The Senior Vice President and Head of Obesity and Metabolic Disorders is a new position at Orexigen. Dr. Kim will report to Eduardo Dunayevich, M.D., Chief Medical Officer.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... treasurer for the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association (HBA). ... The HBA Mid-Atlantic chapter board meets in person once each quarter and holds ...
(Date:5/24/2017)... ... May 23, 2017 , ... Federal funding for basic and applied scientific research ... medical and other vital technologies — deserves continued support, say leaders of SPIE, ... community today in responding to the President’s budget request for Fiscal Year 2018. , ...
(Date:5/23/2017)... Toronto, Canada (PRWEB) , ... May 23, 2017 ... ... of Firmex FileSend, a cloud-based file transfer solution that makes it easy for ... firewall without having to worry about cumbersome FTP software or email file size ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading ... marking the occasion with a strong presence at Bio-IT World Conference & Expo ... extends an invitation to all attendees to view posters on the entire ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):